Advancements in cardiac gene editing are poised to reshape the landscape of cardiovascular medicine. This groundbreaking field involves the precise modification of the genetic code within cardiac cells, offering a revolutionary approach to addressing the root causes of heart diseases. Molecular tools such as CRISPR-Cas9 are at the forefront, enabling researchers to target and edit specific genes linked to cardiovascular conditions. This transformative technology holds the potential to usher in personalized therapeutic interventions, opening new vistas for treating congenital heart disorders, genetic predispositions, and various cardiovascular ailments. Although still in the nascent stages of development, cardiac gene editing represents a cutting-edge avenue that not only enhances our understanding of cardiac health but also holds immense promise for pioneering tailored treatments for individuals with diverse cardiovascular conditions.
Title : Chronic angina and the health economics of cardiovascular risk reduction in macro- and microvascular coronary disease
Uwe Peter Tigor, Auxilius Pharma, United States
Title : Vericiguat Inhibits the Progress of Cardiac Hypertrophy and Prevents Hypertrophy Induced Heart Failure by Multiple Mechanisms
Guo Wei He, Tianjin University, China
Title : Not So Idiopathic After All: Genotype, Phenotype and IL-1 Blockade Response Converge in Recurrent Pericarditis
burcu yagmur, Kyrenia University Hospital, Cyprus
Title : Beyond the Heart in Cardiovascular Magnetic Resonance Imaging: Prevalence and Clinical Significance of Incidental Extracardiac Findings
burcu yagmur, Kyrenia University Hospital, Cyprus
Title : Cardiovascular mortality in colon cancer a patient characteristics analysis: Population-based study
Nouf, KAU, Saudi Arabia
Title : Improving Screening and Treatment of Iron Deficiency in Patients with Heart Failure with Reduced Ejection Fraction: A Two-Cycle Quality Improvement Project
Danish Malik, University Hospitals Dorset NHS Foundation Trust, United Kingdom